Discordance between Surface and Cytoplasmic Expression of the Leu-4 (T3) Antigen in Thymocytes and in Blast Cells from Childhood T Lymphoblastic Malignancies

Michael P. Link, Stanford J. Stewart, Roger A. Warnke, and Ronald Levy
Departments of Pediatrics, Medicine, and Pathology, Stanford University School of Medicine, Stanford, California, and Division of Hematology/Oncology, Children’s Hospital at Stanford, Palo Alto, California 94304

Abstract

We have examined the expression of the Leu-4 (T3) antigen on the cell surface and in the cytoplasm of blast cells from 23 patients with T cell acute lymphoblastic leukemia and T cell lymphoblastic lymphoma. In the majority of cases (17), the Leu-4 antigen was absent from the cell surface; however, in 16 of these 17 cases, blast cells demonstrated cytoplasmic expression of Leu-4. This discordance between surface and cytoplasmic expression of Leu-4 was also found in thymocytes and appeared to be restricted to Leu-4, in that tests of other T cell antigens merely revealed discordance between surface and cytoplasmic expression. To study further the cytoplasmic determinant identified by anti-Leu-4 in malignant T lymphoblasts, immunoprecipitation studies were performed that utilized biosynthetic labeling of established T cell lines derived from T lymphoblastic malignancies. By one-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis, identical Leu-4 polypeptide families were immunoprecipitated from surface Leu-4+ and surface Leu-4+/cytoplasmic Leu-4+ cell lines. Because T lymphoblastic malignancies represent proliferations of immature T cells, and because the cases studied demonstrated surface phenotypes corresponding to all of the proposed stages of T cell ontogenesis, it appears that cytoplasmic expression of Leu-4 occurs early in T cell development. The reason for the failure of these immature T cells to transport the Leu-4 molecule to their surface remains to be elucidated.

Introduction

Studies of immunologic membrane markers of malignant cells from human lymphoid leukemias and lymphomas have revealed the heterogeneous nature of these diseases. The majority of these malignancies now are known to be neoplasms that originate in cells at various stages of maturation in T or B lineage (1–6). Analysis of cases of T lineage malignancy with a series of monoclonal antibodies has provided important insights into the heterogeneity within the subset of T cell lymphoproliferations (7–13). These studies of malignant cells in conjunction with studies of normal lymphocytes of T cell lineage from peripheral blood, thymus, and other tissues have added considerably to our understanding of normal T cell ontogeny. A model for T cell maturation has been proposed based upon these studies in which the stages of T cell maturation are characterized by profound changes in cell surface antigen expression (7, 9, 10). According to this model, cells at the earliest stage of T cell ontogeny (which express the T9 and T10 antigens) acquire the thymocyte-specific antigen, Leu-6 (T6), as well as “helper” and “suppressor” antigens (Leu-3 and Leu-2 [T4, T5]) with further maturation to the “cortical thymocyte” stage. The segregation of T cells into helper (Leu-2+/Leu-3+) and cytotoxic/suppressor (Leu-2+/Leu-3−) populations occurs in the late stages of intrathyic maturation as cells acquire antigenic profiles which resemble the phenotypes of mature T cells found in the peripheral blood compartment. A feature of this model of T cell ontogeny is that Leu-4 (T3), a pan-T antigen found on mature T cells, is not expressed until the late thymocyte stage when T cell subset commitment is established.

Support for this model of T cell maturation derives from studies of T lymphoblastic malignancies (T cell acute lymphoblastic leukemia [T-ALL] and T cell lymphoblastic non-Hodgkin’s lymphoma [T-NHL]), which are presumed to arise from immature T cells. The majority (although not all) of cases studied demonstrate surface antigenic profiles consistent with the proposed stages of T cell maturation, thus supporting the concept that malignant cells in these lymphoproliferations represent the progeny of a transformed cell frozen at one point in normal cellular differentiation. As predicted by the model, blast cells from the majority of cases of T lymphoblastic malignancies do not express the Leu-4 antigen (7–13); thus, the majority of cases of T-ALL and T-NHL are presumed to arise from early and mid-thymocytes.

We have examined cases of T lymphoblastic malignancies for surface as well as cytoplasmic expression of T cell antigens, and we have found a discordance between surface and cytoplasmic expression of the Leu-4 antigen. As in previous reports, the Leu-4 antigen is absent, or weakly expressed, on the cell surface in the majority of cases. However, in virtually all cases of T-ALL and T-NHL, intracellular Leu-4 antigen is found in blast cells even when the antigen is absent from the cell surface.

Methods

Monoclonal antibodies. Monoclonal antibodies Leu-1 (Pan-T), Leu-2a (T cytotoxic/suppressor), Leu-3a (T helper), Leu-4 (Pan-T), Leu-5 (E rosette receptor), Leu-6 (thymocyte), Leu-9 (T-ALL/NHL), Leu-12 (B
cell), HLA-DR, and CALLA (common acute lymphoblastic leukemia antigen) were generously supplied by the Becton-Dickinson Monoclonal Center (Mountain View, CA). Monoclonal antibodies OKT9 (transferrin receptor) and OKT10 were purchased from Ortho Pharmaceuticals (Raritan, NJ). Monoclonal antibody B1 was purchased from Coulter Laboratories (Hialeah, FL). The methods of development of these reagents and the distribution of the antigens detected by these reagents on normal tissues and malignant cells have been reported previously (7, 12–21).

Patients and cells. Malignant cells were obtained from patients at the time of initial presentation or relapse after informed consent was obtained. Tissue analyzed included lymph nodes, pleural effusions, bone marrow, and peripheral blood. Only specimens containing >80% malignant cells were analyzed. The diagnosis in each case was established by standard morphologic and histochemical parameters. Normal thymus glands were obtained from fresh surgical specimens.

Immunophenotyping studies were performed on cells in single-cell suspension and also in tissue section. Cell suspensions were made from leukemia and lymphoma cells which were isolated from heparinized bone marrow, peripheral blood, and malignant effusions by Ficoll-Hypaque density sedimentation. Single-cell suspensions were also made from lymphomatous masses and lymph nodes which were gently teased and passed through a stainless steel mesh. In the majority of cases, immunophenotyping studies were performed on cell suspensions when first obtained, but in some cases immunophenotype analysis was performed on cells cryopreserved by using standard techniques and stored at −196°C in 10% dimethylsulfoxide and 10% fetal calf serum. There was no difference in cell surface markers when performed sequentially on fresh and frozen cells.

The cell lines 255.88 (22) (a T-T hybrid line) and HPB-ALL (23) were utilized in these studies. Characteristics of these lines have been previously described.

Immunophenotyping studies. Cell surface antigens were identified by the binding of monoclonal antibody detected by indirect immunofluorescence. One million cells were placed in plastic tubes and incubated with 1 μg of purified monoclonal antibody at 4°C for 20 min. Cells were washed twice in the cold in phosphate-buffered saline plus 0.02% sodium azide to remove excess antibody, and incubated for 20 min at 4°C with fluorescein isothiocyanate-conjugated goat anti-mouse immunoglobulin (Tago Inc., Burlingame, CA). The cells were washed twice, fixed in 1% formaldehyde in phosphate-buffered saline, and analyzed for fluorescence staining with a fluorescence-activated cell sorter equipped with a log amplifier (FACS IV, Becton, Dickinson Electronics Laboratory, Mountain View, CA) interfaced with a Consort 440 computer system. The intensity of fluorescence for 10,000 cells in each sample was determined and the results were displayed as a histogram by plotting the fraction of total cells versus intensity of fluorescence for each antibody. Background fluorescence was determined by incubating the cells with a nonreactive myeloma protein in place of specific antibody. The cell population from an individual patient was felt to be reactive with an antibody if >20% of cells demonstrated specific fluorescence when compared with the background control.

Immunologic phenotyping of frozen tissue sections was performed by utilizing a biotin-avidin–horseradish peroxidase technique, as previously reported (24). Representative portions of fresh surgical biopsy specimens were snap-frozen, sectioned, and acetone-fixed before staining. The frozen sections were sequentially stained with unconjugated monoclonal antibody followed by biotinylated goat anti-mouse IgG (Tago Inc.) or horse anti-mouse IgG (Vector Laboratories, Inc., Burlingame, CA) followed by avidin–horseradish–peroxidase conjugate (Vector Laboratories). Individual cells were identified on the basis of characteristic histologic features and antigen expression. As in the cell suspension studies, isotype-matched nonreactive myeloma proteins were used as controls for background staining.

Cytocentrifuge preparations were prepared from the single-cell suspensions by utilizing a Shandon cytocentrifuge (Shandon Cytospin 2, Shandon Southern Instruments, Inc., Sewickley, PA). Multiple samples, ~150,000 cells each, were centrifuged onto glass slides, fixed in acetone, and then stained by utilizing the biotin–avidin–horseradish peroxidase technique as described above. Immunophenotyping of tissue sections and cytocentrifuge preparations after fixation reveals intracellular as well as surface antigen expression (25–28).

In immunophenotypic analysis of Leu-4 antigen, HPB-ALL and 255.88 cells, ~2 × 10⁸, were harvested in logarithmic growth phase, washed twice in Dulbecco’s phosphate-buffered saline, and resuspended in cytochrome-/methionine-free RPMI-1640 medium (Selectamite kit, Gibco Laboratories, Grand Island, NY) supplemented with 10% dialyzed, heat-inactivated fetal calf serum. After a 45-min preincubation at 37°C in a 5% CO₂ environment, 1.0 mL each of [35S]cysteine (1,076 Ci/mmol), and [35S]methionine (1,064 Ci/mmol) (New England Nuclear, Boston, MA) were added. Incubation of cells was continued for 120 min. Cells were harvested by centrifugation, washed twice, in Dulbecco’s phosphate-buffered saline, and lysed in 0.5% NP-40 (BDH, Gallard and Schlesinger, New York) lysis buffer containing Tris-HCl 50 mM, pH 7.4, NaCl 0.15 M, EDTA 5 mM, phenylmethylsulfonyl fluoride 2 mM, aprotinin 0.2 TIU/ml (Sigma Chemical Co., St. Louis, MO), and iodoacetamide 25 mM (Eastman Kodak Co., Rochester, NY) on ice. Nuclei were removed and lysates clarified by centrifugation. Cell lysates were precleared with immunoprecipitates formed in situ by the addition of an irrelevant class-matched IgG1 antibody L368 (anti-β-2-microglobulin) 10 μg, and goat anti-mouse IgG (EY Labs, San Mateo, CA) at 4°C over 6 h while slowly rotating. Specific immunoprecipitation, using 10 μg of specific, purified, anti-Leu-4 antibody and goat anti-mouse IgG at equivalence, was performed in a similar fashion over 18 h. Precipitates were collected by centrifugation and washed six times in NaCl-EDTA-Tris buffers containing NaCl 0.15 M, EDTA 5 mM, Tris-HCl 50 mM, pH 7.4, Na azide 0.02%, NP-40 decreasing from 1 to 0%, and additional NaCl to 0.5 M in the first four washes. One-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of samples was carried out on 10% acrylamide gels as described previously by Laemmli (29).

Results

10 cases of T cell acute lymphoblastic leukemia and 13 cases of T cell lymphoblastic lymphoma were studied for both surface and cytoplasmic antigen expression. In all cases, the diagnosis was confirmed by examination of appropriately stained tissue by utilizing standard morphologic criteria. The T cell lineage of these malignancies was confirmed by the reactivity of blast cells with one or more T lineage antibodies. In all 22 cases tested, blast cells were reactive with anti-Leu-9. We and others have shown previously that expression of the 40,000 mol wt antigen defined by Leu-9 (4H9) (30) and its equivalents (WT1 [30], 3A1 [31]) reliably confirms T cell lineage among the childhood lymphoblastic leukemias and lymphomas.

Results of surface immunophenotyping of malignant cells in suspension are shown in Table I. As in other series of T-ALL and T-NHL, the majority (17 of 23) of cases were Leu-4 negative. In all Leu-4-negative cases, <15% of cells expressed the Leu-4 antigen, and among the Leu-4-positive cases, expression of Leu-4 was generally weak; in only two cases was Leu-4 expressed by >50% of the malignant cells.

In 13 cases (NHL-9, ALL-4), cell suspensions and frozen sections were made from identical tissue allowing direct comparison of the two techniques of immunophenotyping. In 10 additional cases where frozen tissue was not available, cytocentrifuge preparations were made from the cell suspension, fixed, and then processed like tissue sections. On the one hand, results of staining of frozen tissue sections and cytocentrifuge
Table I. Results of Surface Immunophenotyping

<table>
<thead>
<tr>
<th>Case</th>
<th>Leu-1</th>
<th>Leu-2</th>
<th>Leu-3</th>
<th>Leu-4</th>
<th>Leu-5</th>
<th>Leu-6</th>
<th>Leu-9</th>
<th>T</th>
<th>T</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALL</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>NT</td>
<td>-</td>
<td>+</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>1</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>NT</td>
<td>-</td>
<td>+</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>2</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>4</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>T</td>
<td>T</td>
<td>T</td>
</tr>
<tr>
<td>5</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>6</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>7</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>8</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>9</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>10</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
</tbody>
</table>

NHL

<table>
<thead>
<tr>
<th>Case</th>
<th>Leu-1</th>
<th>Leu-2</th>
<th>Leu-3</th>
<th>Leu-4</th>
<th>Leu-5</th>
<th>Leu-6</th>
<th>Leu-9</th>
<th>T</th>
<th>T</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>12</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>13</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>14</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>15</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>16</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>NT</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>17</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>18</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>19</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>20</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>21</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>22</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>23</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

NT, not tested.

preparations after acetone fixation have been identical in our laboratories (Link, M. P., and R. A. Warnke, unpublished data). On the other hand, it has been reported previously that fixation of cells or tissue before immunologic staining results in demonstration of intracytoplasmic as well as surface antigens whereas staining of unfixed cells in suspension demonstrates only surface antigens (25–28). 148 tests for T cell antigens were performed in the 23 cases. Excluding testing for Leu-4, there was concordance of results for 116 of 125 (93%) antigens tested in fixed and unfixed cells (Table II). Of the nine discordant results, most reflected weak antigen expression as detected by one technique which was scored as negative by the other.

Results of testing for Leu-4 in fixed and unfixed cells demonstrated markedly discordant results. Malignant cells from 17 cases did not express Leu-4 on the cell surface, yet, in all but one of these cases (94%), fixed cells were strongly reactive with anti-Leu-4. The results of one such case (case 19) are shown in Fig. 1. In an additional six cases, the blast cells expressed Leu-4 on the cell surface and testing of fixed cells from these cases also revealed strong expression of Leu-4. In only one of the 23 cases studied, fixed cells were found to be Leu-4 negative (case 11). In that fixation of cells before staining allows for the detection of intracellular as well as surface antigens, anti-Leu-4 apparently reacts with an intracellular determinant in T lymphoblastic malignancies.

The T lymphoblastic malignancies are presumed to derive from thymocytes at various stages of maturation. To examine if discordance of Leu-4 expression on the cell surface and in cytoplasm is a feature of normal T cell ontogeny or a feature unique to malignant cells, normal human thymocytes obtained from surgical specimens were examined for Leu-4 expression. When studied in cell suspension ~35–40% of thymocytes were found to express surface Leu-4. Study of thymocytes in frozen section after fixation revealed that >90% of thymocytes (including cortical thymocytes) are reactive with anti-Leu-4.

To study further the intracellular determinant identified by anti-Leu-4 in malignant T lymphoblasts, immunoprecipitation studies were performed utilizing established T cell lines derived from T lymphoblastic malignancies. The HPB-ALL cell line expressed the Leu-4 antigen on the cell surface, whereas the 255.88 cell line (a derivative of the Jurkat cell line) demonstrated discordant Leu-4 expression when studied in cell suspension and in cytocentrifuge preparations after fixation. The two cell lines were biosynthetically labeled with [35S]cysteine and [3H]methionine; immunoprecipitation with anti-Leu-4 and analysis of the two cell lines by SDS-PAGE were then run in parallel. As demonstrated by the gel tracks in Fig. 2, biosynthetically labeled material reactive with anti-Leu-4 was immunoprecipitated from both cell lines. This

Table II. Summary of Cases Analyzed for Surface and Cytoplasmic Antigens

<table>
<thead>
<tr>
<th>Dx</th>
<th>Cases</th>
<th>Tissue/ Cyto-prep</th>
<th>Surface Leu-4</th>
<th>Cytoplasmic Leu-4</th>
<th>Concordance at other antigens tested</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td></td>
</tr>
<tr>
<td>ALL</td>
<td>10</td>
<td>6/6</td>
<td>6</td>
<td>6</td>
<td>47/51</td>
</tr>
<tr>
<td>NHL</td>
<td>13</td>
<td>9/4</td>
<td>11</td>
<td>10</td>
<td>69/74</td>
</tr>
<tr>
<td>Total</td>
<td>23</td>
<td>13/10</td>
<td>17</td>
<td>16</td>
<td>116/125 (93%)</td>
</tr>
</tbody>
</table>

Figure 1. Comparison of cell suspension staining analyzed by FACS and tissue section staining of case 19. The FACS histogram demonstrates virtual absent reactivity with anti-Leu-4 when compared with an irrelevant isotype-matched control myeloma protein. By contrast, low- and high-power micromicrographs from immunophenotyping studies done in tissue section demonstrate strong reactivity with anti-Leu-4 indicated by dark staining cells (C and D) compared with staining with control myeloma protein (A and B).
Moreover, cells in demonstrated T-ALL restricted thymocytes of cases of T-ALL (74%) of cases of T-ALL. The finding for 255.88 was superimposable upon that obtained using an irrelevant isotype-matched control, confirming that this cell line is surface Leu-4 negative. On the right, SDS-PAGE analysis of Leu-2 (lanes A and D), Leu-3 (lanes B and E), and Leu-4 (lanes C and F) specific immunoprecipitates from 255.88 (lanes A–C) and HPB-ALL (lanes D–F) compares antigen metabolically labeled with radioactive amino acids, methionine and cysteine. Arrows point to the family of molecules immunoprecipitated by anti-Leu-4.

Moreover, by one-dimensional SDS-PAGE analysis, the major polypeptide families of Leu-4 immunoprecipitated from the two cell lines appeared indistinguishable. Over the 2-h labeling period, as much or more anti-Leu-4-reactive material was synthesized by cell line 255.88, which is surface Leu-4 negative.

Discussion

The Leu-4 (T3) antigen consists of a family of glycoprotein molecules of ~25,000 mol wt on the surface of all peripheral blood T cells and 30–60% of thymocytes. This antigen is not found on the surface of leukocytes outside the T cell lineage. The absence of this molecule on the surface of the majority of thymocytes and the majority of cases of T-ALL and T-NHL, which are presumed to be derived from thymocytes, has led investigators to conclude that expression of Leu-4 is restricted to mature thymocytes and T cells.

In this report, 23 cases of T-ALL and T-NHL have been studied for surface as well as intracellular expression of Leu-4. As in other series, we found that blast cells from the majority (74%) of cases of T-ALL and T-NHL failed to express the Leu-4 antigen on the cell surface. However, we have demonstrated a discordance between surface and cytoplasmic expression of Leu-4 in T lymphoblastic malignancies. Discordance in results of testing for Leu-4 between fixed and unfixed cells was found in 16 of 23 cases (70%) compared to a discordance rate of only 7% for all other antigens tested. Moreover, six of the cases studied were surface Leu-4+ where no discordance could be detected. Thus, of 17 cases which were surface Leu-4 negative, 16 (94%) expressed intracellular Leu-4.

One potential explanation of the discordant results of testing is cross-reactivity of the anti-Leu-4 antibody with another determinant modified by the fixation process. However, immunoprecipitation of a family of polypeptides indistinguishable from the Leu-4 antigen from the surface Leu-4+ cell line 255.88 supports the concept that the determinant recognized in fixed cells from T lymphoblastic malignancies is, in fact, the Leu-4 antigen. The cytoplasmic form of the Leu-4 antigen does not appear to be a precursor molecule because the molecular weight of the polypeptide is not different from that found in cells expressing surface Leu-4 (Fig. 2); nor is it different from the molecular weight previously reported in mature T cells. The explanation for the apparent intracellular limitation of the Leu-4 antigen and failure of surface expression in malignant T cells and thymocytes is unknown.

Discordance between surface and cytoplasmic antigen expression has been noted previously in other leukocytes, and, in some instances, the lineage specificity of certain antigens has been challenged because of these findings. For example, intracytoplasmic expression of the Leu-4 (T3) antigen has been demonstrated in normal monocytes and B chronic lymphocytic leukemia cells (27, 28). In our study of T lymphoblastic malignancies, we examined intracellular expression of several putatively B lineage-specific antigens as well (data not shown). We did not detect intracytoplasmic expression of B lineage antigens in any of these cases. Nor did we note a consistent discrepancy between surface and cytoplasmic antigen expression for any but the Leu-4 antigen. However, the consistent discordance in Leu-4 expression in T lymphoblastic malignancies and discordances noted by other investigators suggest that the repertoire of antigen expression of a cell should not be inferred from studies of surface antigen expression alone.

In our study of T-ALL and T-NHL, cases representing all stages of thymocyte development were examined, and only one failed to express intracellular or cell surface Leu-4. This case (no. 11) would be classified in the earliest stage of T cell development expressing only the Leu-1, Leu-9, and T10 antigens. Other cases in our study expressing the early thymocyte phenotype (cases 1–3 and 12–14) did demonstrate intracellular but not surface Leu-4. The finding that virtually all normal thymocytes and malignant T cells (even those expressing the early thymocyte phenotype) express Leu-4, at least intracellularly, suggests that expression of cytoplasmic Leu-4 must occur very early in T cell development.

An analogous situation where a cellular antigen is detectable in the cytoplasm before its expression on the cell surface has been noted in studies of B cell ontogeny (3, 33–35), where cytoplasmic expression of the heavy chain of immunoglobulin occurs early in B cell maturation at the so-called "pre-B stage" before surface immunoglobulin expression. Lymphoid leukemias (3, 4) and lymphomas (36) with this pre-B phenotype have been identified, and these cases of pre-B ALL and NHL have been cited to support the concept that lymphoid neoplasms represent clonal expansions of cells frozen at discrete stages of lymphocyte maturation. Further studies of lymphoid neoplasms of B lineage have revealed the molecular events that occur at different stages of B cell development. Commitment to immunoglobulin synthesis has been shown to occur at the earliest stage of B cell ontogeny (37, 38). Studies of T cell neoplasms
indicate that an analogous series of events occurs in T cell development. Recent studies of thymocytes, of tumor cells from patients with T lymphoblastic leukemia and lymphoblastic lymphoma (39), and of cell lines derived from thymic leukemias (40) have demonstrated that rearrangements of the gene for the T cell receptor occurs in immature cells of T lineage that express the early thymocyte phenotype. Apparently, rearrangement of the T cell receptor gene occurs early (if not at the earliest stage) in T cell ontogeny. Our studies indicate that synthesis of the Leu-4 antigen, a molecule which is critical to the function of the mature T-cell, likewise occurs in immature T cells, and may precede the rearrangement of the T cell receptor gene inasmuch as the Leu-4 antigen can be found in cells expressing even the most immature thymocyte phenotype.

The pivotal role of the Leu-4 antigen in the function of the mature T cell is now recognized. Recent studies have demonstrated that the T cell receptor is noncovalently linked to Leu-4 (T3) on the cell surface (41–43). Moreover, experiments that mutate variants of the Jurkat T cell leukemia line (44) suggest an intimate interdependence in the surface expression of the Leu-4 and T receptor molecules; surface expression of neither of these molecules occurs without co-expression of the other. In that the Leu-4 antigen is not expressed on the cell surface until late in T cell ontogeny, antigen specificity is not conferred upon the maturing T cell until late in T cell development. From our study, it is apparent that the Leu-4 molecule can be demonstrated intracellularly early in T cell ontogeny. Because the intracellular Leu-4 antigen is apparently similar to the surface-expressed polypeptide, it is not clear why expression is restricted to the cytoplasm. It is possible that synthesis of the Leu-4 antigen precedes the synthesis of at least part of the T cell receptor heterodimer in T cell ontogeny. As in the pre-B cell where the immunoglobulin heavy chain is restricted to the cytoplasm until light chain synthesis occurs (45), the surface Leu-4/–cytoplasmic Leu-4+ T cell leukemias may represent an early stage of T cell development where the Leu-4 portion of the T cell receptor complex is restricted to the cytoplasm before synthesis of the T cell receptor heterodimer. Studies are now underway to test this hypothesis.

Acknowledgments

We gratefully acknowledge the technical assistance of Catherine Carswell and Jane Bindl. We thank Delores Dewey and Luella Walter for their excellent secretarial assistance during the preparation of this manuscript. This work was supported in part by grants CA-21223, CA-32739, and CA-34233 from the National Institutes of Health. Dr. Stewart is a recipient of grant PRTF3 from the American Cancer Society.

References


